

AUTHOR INDEX

VOLUME 22

- Adam, Dieter, 353
 Adelman, Lee A., 442
 Adelman, Martin, 800
 Ahonkhai, Vincent I., 715
 Albhorn, W. E., Jr., 824
 Alexander, Gary A., 162
 Allen, N. E., 824
 Alliegro, George M., 652
 Altés, A. Gutiérrez, 1064
 Andrews, J. M., 969
 Anton, P. A., 312
 Arena, Adriana, 1067
 Assael, Baroukh M., 1017
 Atherton, Frank R., 571
 Auckenthaler, R., 448
 Avila, José L., 380
 Ayers, Leona W., 859
 Azimi, Parvin H., 923
- Bächi, Brigitte, 323
 Bagwell, Charles B., 431
 Bakker-Woudenberg, Irma
 A. J. M., 1042
 Bal'a, Farid, 1087
 Ballard, Ronald C., 598, 686
 Bally, Rene, 678
 Bansal, Madhu B., 350
 Barry, Arthur L., 859
 Barton, L. J., 218
 Barza, Michael, 832
 Batzinger, R. P., 707
 Bawdon, Roger E., 999
 Beale, Angela S., 369
 Beaudet, R., 277
 Beneke, Everett S., 810
 Bennett, John E., 482
 Bennett, William M., 508
 Benziger, David P., 475
 Berenguer, José, 1070
 Berens, Randolph L., 657
 Bernacki, Ralph J., 1008
 Bettin, Kristine M., 336
 Beville, Rose, 10
 Bilgeri, Yvonne R., 686, 689
 Birk, R. J., 628
 Bisailon, J. G., 277
 Black, Henry R., 94, 704
 Blair, Donald C., 376
 Böck, August, 231
 Bodey, Gerald P., 43, 513
 Boelaert, Johan, 535
 Bohnhoff, Marjorie, 926
 Bond, Melanie, 515
 Bonina, Letterio, 1067
 Bonner, Daniel P., 172
 Bonner, Mary C., 901
 Boon, Ronald J., 369
 Booth, S. James, 701
- Borner, Klaus, 949
 Boujnah, A., 1084
 Boyce, John M., 901
 Bradsher, Robert W., 36
 Brier, Gordon L., 94
 Brisson, Cynthia J., 1022
 Britten, John, 193
 Brodeur, James P., 652
 Bueding, E., 707
 Bush, Karen, 414
 Butler, Thomas, 312
 Buys, L. F. M., 593
- Calderwood, Stephen B., 266
 Canawati, Hanna N., 906
 Canonico, Peter G., 696
 Caplan, Ellis, 193
 Casal, Julio, 222
 Casanova, Maria A., 380
 Casero, Robert A., Jr., 1008
 Caufield, Page W., 115
 Cavanna, Graziella, 1017
 Chabbert, Yves A., 942
 Chakravorty, Maharani, 541
 Chance, Deborah, 499
 Cherian, Ukken O., 1026
 Cherubin, Charles E., 715
 Childs, George E., 981
 Chrane, Dale, 622
 Chrane, Dale F., 990
 Chung, Menger, 1017
 Citron, Diane M., 226
 Clark, James E., 709
 Clark, Stephen J., 493
 Clausen, Carla, 442
 Clewell, Don B., 204
 Cobbs, C. Glenn, 1
 Colón-Whitt, Alba, 1051
 Comber, Keith R., 369
 Conrad, Robert S., 1012
 Cowlshaw, Anthony, 198
 Crawford, Sharon A., 162
 Crokaert, F., 346
 Crosby, Mark A., 398
 Crossley, K., 648
 Crossley, Kent, 391
 Cullinane, Joanne C., 791
 Cullmann, Wolfgang, 302
 Cynamon, Michael H., 1079
- Daly, Richard C., 461
 Dámaso, Diego, 255
 Danders, W., 785
 Dankert, Jacob, 1073
 Daschner, F. D., 958
 Davidson, David E., Jr., 981
 de Clercq, Erik, 421
- DeFehr, Joan, 508
 Defever, Keith S., 810
 deJongh, Carlos A., 193
 Del Rio, Maria, 622
 del Rio, Maria de los A., 990
 de Pedro, Miguel A., 1070
 DeSante, Karl A., 94
 De Schepper, P. J., 237
 Devaud, Marlyse, 323
 de Visser, Iris, 353
 DeYoung, Donald R., 148
 Dhawan, Vinod K., 350
 Diven, Warren, 839
 Diven, Warren F., 1076
 Doehring, Richard O., 137
 Dorman, C. J., 912
 Dornbusch, Kathrine, 743
 Dougherty, Edward M., 527
 Dowling, John N., 272
 Doyle, Ronald J., 83
 Dubes, George R., 701
 Ducey, Kevin, 201
 Dudek, Edward J., 926
 Duggan, David O., 376
 Dulworth, Jacqueline K., 635
 Duncan, Margaret O., 686
 Dunphy, Mary G., 923
 Durack, D. T., 448
 Dyas, A., 969
- Eckfeldt, John H., 878
 Edelson, Jerome, 475
 Edelstein, Paul H., 90
 Eley, Adrian, 198
 Eliopoulos, George M., 295
 Elliott, Ann M., 1
 Elliott, Greg R., 781
 Elliott, W. Clayton, 508
 Elvers, Anke, 949
 Elwell, Lynn P., 882
 Enciso, M. Diez, 1064
 Eng, Robert H. K., 522
 Ernest, Karen D., 154
 Evans, Evan, 800
 Evans, Martin E., 334
- Fainstein, Victor, 513
 Fasching, Claudine E., 336
 Fass, Robert J., 28, 165
 Feingold, David S., 470
 Ferreira, Maria C., 832
 Field, Hugh J., 719
 Finegold, Sydney M., 226, 338
 Finley, Rebecca S., 193
 Fitzgerald, Robert H., Jr., 461
 Fling, Mary E., 882
 Flynn, Kerrie, 47

- Follath, Ferenc, 954
 Fontijne, Peter, 364, 386
 Fort, Raymond C., 1031
 Fortner, Clarence L., 193
 Foster, T. J., 912
 Foulstone, Mark, 753
 Fox, Lawrence M., 431
 Freiberg, Mark R., 781
 Freudenberger, Joan S., 414
 Fuchs, Peter C., 859
 Fujiu, Morio, 617
 Fukuoka, Y., 728
- Galloway, Karen S., 55, 1026
 Garcia-Rodriguez, J. A., 893
 Garcia-Sanchez, J. E., 893
 Gardella, Amelie, 266
 Gavan, Thomas L., 859
 Genta, Valerio M., 151
 Gentry, Layne O., 32
 Georgopapadakou, Nafsika H., 172
 Geraci, J. E., 448
 Geraci, Joseph E., 972
 Gerding, Dale N., 336, 844, 878
 Gerlach, E. Hugh, 859
 Gershon, Herman, 805
 Gezeliu, Lena, 743
 Giger, Donald K., 1037
 Gilbert, David N., 508
 Gilbertson, John R., 805
 Gilleland, H. E., Jr., 1012
 Gillin, Frances D., 342
 Glatzer, Lou, 204
 Gnann, John W., Jr., 1
 Goering, Richard V., 1037
 Goessens, Wil H. F., 364
 Goetter, William E., 1
 Goldmann, Donald A., 47
 Goodbody, M. M., 218
 Goodbach, Sherwood L., 771
 Grant, Robert B., 142
 Greenwood, David, 198
 Greer, Sheldon B., 431
 Gump, Dieter W., 398
 Guss, Stephen P., 999
 Gutmann, Laurent, 128
 Gwaltney, Jack M., Jr., 639
- Haas, Dieter, 242
 Hadley, W. Keith, 711
 Hajdu, Richard, 62
 Hall, Michael J., 571
 Hallander, Hans O., 743
 Haller, I., 165
 Hampel, Barbara, 1061
 Hansbrough, John F., 709
 Harding, G. K. M., 895
 Harding, Stuart M., 995
 Harrington, Joyce E., 71
 Hasegawa, Toru, 735
 Hassall, Cedric H., 571
 Hayden, Frederick G., 639
 Hebertson, Richard, 643
 Heessen, Frans W. A., 520
- Hegarty, A., 969
 Hemmann, Renate, 954
 Hemmer, K. A., 958
 Hemsell, David L., 999
 Hennessy, J. N., 218
 Henning, Claes, 1058
 Herrick, Melanie, 151
 Himuro, Shozo, 250
 Hiruma, Ryoichi, 585
 Hobbs, J. N., Jr., 824
 Hodges, Brenda, 995
 Hodges, Glenn R., 909
 Hof, Herbert, 332
 Hohenfeldt, Paul R., 698
 Hoidal, John R., 781
 Holloway, Yvette, 1073
 Holmes, Barbara, 10
 Homberger, Françoise, 15
 Hooper, David C., 662
 Horchani, A., 1084
 Houghton, Donald C., 508
 Huggins, John W., 696
 Humphries, Nicola L. M., 170
- Inami, Akiko, 585
 Ingram, Robert L., 1031
 Inoue, Matsuhisa, 181, 548, 564, 579, 693, 721
 Iravani, Abdollah, 672
 Ishitsuka, Hideo, 611, 617
 Israel, Karen S., 94
 Iyobe, Shizuko, 358
 Izumiya, N., 785
- Jackson, George G., 1004
 Jacobs, M. R., 312
 Jacobs, Michael R., 897
 Jacobson, Jay A., 643
 Jacobson, Karin, 743
 Jacobus, Nilda V., 771, 832
 Jacoby, George A., 266, 525
 Jaffe, Aline, 942
 Jansson, Lorita, 1058
 Jenkins, Stephen G., 628
 Johnson, Catherine E., 406
 Johnson, Jonas, 1076
 Jolliffe, Linda K., 83
 Jones, Ronald N., 859, 985
 Jorgensen, James H., 162
 Joshi, Arati, 541
 Jules, Kety, 453
- Kager, Lars, 208
 Kahan, Frederick M., 62
 Kamimura, Toshiaki, 560
 Kaneko, Midori, 585
 Kantarjian, Hagop, 1087
 Karlsson, Inga, 743
 Karran, Stephen J., 170
 Kasworm, Evelyn, 643
 Kato, Masuhiro, 721
 Kato, T., 785
 Kato, Takako, 358
- Katsu, Kanemasa, 181
 Kawana, Nobuko, 585
 Kayser, F. H., 323
 Kayser, Fritz H., 15
 Kelly, Frances, 897
 Kemp, J. A., 312
 Kennell, Wiebke L., 55
 Kikuchi, Y., 935
 Kim, H., 848
 Kirst, H. A., 824
 Kitoh, Kyosuke, 181
 Klustersky, J., 330, 604
 Klayman, Daniel L., 981
 Kleinkauf, H., 785
 Knight, Vernon, 108
 Kobayashi, Fujio, 564
 Kobayashi, Yoriko, 775
 Koeppe, Peter, 353, 1061
 Komiya, M., 935
 Konthikamee, Wattana, 805
 Koornhof, Hendrik J., 137, 598, 686
 Korhonen, Timo K., 120
 Kos, William L., 698
 Kosui, N., 785
 Koup, Jeffrey R., 442
 Koyama, M., 935
 Krause, M., 785
 Krogstad, Donald J., 917
 Kropp, Helmut, 62
 Kumano, K., 728
 Kuroda, Kyoichi, 308
 Kwan, C., 395
- Laatsch, Linda J., 698
 Labthavikul, Pornpen, 23, 316
 Lagast, H., 330, 604
 Lambert, Annemie, 535
 Lambert, Robert W., 571
 Lambros, Chris, 981
 Landesman, Sheldon, 522
 Langkamp, Herman, 805
 Larson, Tom N., 878
 Lea, A. Scott, 32
 LeFrock, Jack L., 930
 Lerner, Stephen A., 78, 926
 Levandowski, Roland A., 1004
 Levin, Robert M., 923
 Levine, Hillel B., 43
 Levine, Jerome F., 103
 Levy, Jack, 442
 Levy, Stuart B., 791
 Liebowitz, Lynne D., 598
 Liljeqvist, Lars, 208
 Lin, C., 848
 Lindemann, M. L. Mateos, 1064
 Lloyd, William J., 571
 Lockwood, W. R., 901
 Lode, Hartmut, 949, 1061
 Lorian, V., 1084
 Lossick, Joseph G., 409
 Louis, Claude, 678
 Lounatmaa, Kari, 120
 Lower, Richard R., 201
 Lutz, Brobson, 10

- Madoff, Sarabelle, 678
 Magnussen, C. Richard, 154
 Maksymiuk, Andrew W., 43
 Malmborg, Anna-Stina, 208
 Marahiel, M. A., 785
 Marks, M. I., 140
 Marks, Melvin I., 145
 Marmouset, Marie-Claire, 678
 Marr, J. Joseph, 657
 Marrie, T. J., 395
 Maslow, Melanie J., 103
 Mastroeni, Pasquale, 1067
 Matsen, John M., 488, 493
 Matsui, Hidefumi, 213
 Matsumoto, Joseph Y., 972
 Matsuura, Yoshiharu, 548, 579
 Mauff, Alfred C., 686
 McCarron, David A., 508
 McCarthy, Laurence R., 151
 McCracken, George H., Jr., 622, 990
 McHugh, Gail L., 662
 McKinlay, Mark A., 1022
 McMurry, Laura M., 791
 McNamara, Bernard T., 226
 Mead, Karen, 391
 Mee, Brian J., 889
 Mekras, John A., 431
 Mendelman, Paul M., 531
 Mercado, Teresa I., 1051
 Merendino, Rosalba, 1067
 Meunier-Carpentier, F., 604
 Meyer, Richard D., 90
 Michel, Marc F., 364, 386, 1042
 Mikami, H., 728
 Mikami, Hidetada, 693
 Miralles, Joseph V., 1022
 Mitsuhashi, S., 728
 Mitsuhashi, Susumu, 181, 358, 548, 564, 579, 693, 721
 Moellering, Robert C., Jr., 266, 295
 Mogabgab, William, 10
 Molineaux, C. J., 707
 Moody, Frank G., 488
 Morenzoni, Giovanna, 15
 Morlock, C., 648
 Muder, Robert R., 1076
 Müller, Klaus-Michael, 332
 Mullie, A., 237
 Mulligan, Maury E., 226
 Muytjens, Harry L., 520
 Nahmias, André J., 499
 Nakae, Ryoko, 554
 Nakae, Taiji, 554, 775
 Nakagawa, K., 935
 Nakahara, Hideomi, 852
 Nelson, Donald J., 657
 Nelson, John D., 622, 990
 Neu, Harold C., 23, 316, 453, 518, 560
 Newman, Kathryn A., 193
 Nicolle, L. E., 895
 Ninomiya, Yasuyuki T., 617
 Nord, Carl-Erik, 208
 Notsch, John D., 981
 Odds, F. C., 763
 Oden, E., 848
 Offermann, P., 958
 Ogashiwa, Mieko, 693
 Ogawa, Hidemasa, 548
 Ogilvie, Kelvin K., 55, 1026
 Ohiwa, Toshio, 611
 Ohkawa, Mitsuo, 308
 Ohm-Smith, Marilyn J., 711
 Ohnishi, Haruo, 250
 Ohsawa, Chieko, 611, 617
 Okasho, Akira, 308
 O'Keefe, J. Paul, 426
 Okuda, Takao, 213
 Ong, Catherine, 852
 Operkuch, Wolfgang, 302
 Ophem, Kent E., 442
 Orzalesi, Giovanni, 1067
 Osada, Yasuaki, 548
 Osseiran, Maher, 1087
 Pachucki, Constance T., 1004
 Packer, Richard R., 985
 Pai, C. H., 140
 Palmer, Gregory S., 1079
 Pancic, Francis, 1022
 Pankey, George A., 51
 Pannier, Wallace L., 696
 Parravicini, Luigi, 1017
 Parris, Deborah S., 71
 Pasculle, A. William, 272
 Pasiecznik, Karen A., 90
 Patel, Indravadan H., 816
 Patterson, Lyndell S., 334
 Peavy, Duane L., 108
 Penn, Robert G., 1037
 Penn, Robert L., 289
 Penner, J. L., 218
 Pennington, James E., 406
 Perlin, Michael H., 78
 Peters, Jeanne, 499
 Petersen, Bruce H., 704
 Peterson, Lance R., 336, 844, 878
 Peterson, Phillip K., 781
 Pfaller, Michael A., 917
 Philippon, Alain M., 266
 Piendl, Wolfgang, 231
 Pieper, Rolf, 208
 Pierce, Carol V., 369
 Polak, Annemarie, 482
 Polk, Ronald E., 201
 Pollock, Alan A., 103, 816
 Pollock, Bee, 10
 Porter, Carl W., 1008
 Porter, Forbes D., 852
 Powers, Celeste N., 108
 Powers, Robert D., 639
 Preheim, Laurel C., 1037
 Preston, M. A., 218
 Prieto, J., 893
 Prince, Alice S., 525
 Prusoff, William H., 176, 284
 Pyckavet, Monique, 535
 Quie, Paul G., 781
 Radatus, Bruno K., 55
 Radwanski, Elaine, 1017
 Rahal, James J., Jr., 103, 816
 Rashtchian, Ayoub, 701
 Reading, Christopher, 753
 Reddy, B. S., 707
 Redjeb, S. Ben, 1084
 Reichelderfer, Charles F., 527
 Reiner, David S., 342
 Rella, Manuela, 242
 Richard, George A., 672
 Rienehart, Kenneth L., 696
 Rikkers, Layton F., 488
 Riley, Thomas V., 889
 Ringrose, Peter S., 571
 Roberts, Glenn D., 148
 Roberts, Marilyn C., 531
 Robinson, Roy G., 137
 Rodríguez-Tebar, Alfredo, 255
 Rogers, Alvin L., 810
 Rojo, Fernando, 255
 Rolfe, Rial D., 338
 Rolston, Kenneth V. I., 930
 Romagnoli, Mario F., 47
 Rose, Fred, 151
 Rosenthal, Ken S., 1031
 Rotschafer, J. C., 648
 Rotschafer, John C., 391
 Rubenis, Mary, 1004
 Russo, John, Jr., 488
 Russo, Mary E., 488
 Ryan, D. Michael, 995
 Saheb, S. A., 277
 Saikawa, I., 728
 Saino, Yushi, 564, 693
 Salari, Hamid, 145
 Salit, Irving E., 515
 Sammartino, Maria T., 154
 Sanchez de S. Lorenzo, A., 893
 Sande, Merle A., 652
 Sanders, Christine C., 1037
 Sapico, Francisco L., 906
 Sato, Kenichi, 548, 579
 Sato, Yoshiko, 358
 Sawai, Tetsuo, 585
 Sawchuck, Ronald J., 391
 Saxon, Barbara A., 488, 493
 Schaberg, Dennis R., 204
 Schell, W. Michael, 652
 Schell, Ronald F., 930
 Schenk, Worthington G., Jr., 262
 Schentag, Jerome J., 262, 800
 Schimpff, Stephen C., 193
 Schinazi, Raymond F., 499
 Schmitt-Slomska, Janine, 678
 Scholer, Hans J., 482
 Schrire, Leonard, 137
 Schroeder, Edward T., 376
 Scovill, John P., 981
 Scribner, R. K., 140
 Segal, Joseph J., 917
 Semonin, Olivier, 942
 Shelton, Sharon, 622, 990

- Shimada, Noriaki, 976
 Shimada, Shigetoshi, 250
 Shomura, Tomoko, 976
 Shulman, Michael A., 715
 Siber, George R., 47
 Silcox, Vella A., 186
 Silver, Simon, 852
 Sim, Iain S., 421
 Simberkoff, Michael S., 103, 816
 Slanicka, J., 958
 Slim, A., 1084
 Smeltzer, Michael P., 409
 Smith, Arnold L., 442, 531
 Smith, Janice E., 201
 Smith, Kendall O., 55, 1026
 Smith, Sandra A., 172
 Smith, Sharon M., 522
 Sokol, Michael S., 1031
 Solem, Lynn D., 391
 Soll, David R., 810
 Sommers, Herbert M., 859
 Sosa, Anibal, 771
 Speck, William T., 897
 Spencer, George R., 995
 Spiechandler, Jonathan, 816
 Spivack, Jordan G., 176, 284
 Starka, Georges, 678
 Steele Da Cruz, Fernando, 657
 Steigbigel, Roy T., 289
 Steimel, Larry A., 704
 Stephenson, Jane D., 926
 Stevens, David A., 482
 Steward, David L., 635
 Sticht-Groh, Veronica, 332
 Stieglitz, Michaela, 302
 Stiller, Robert L., 482
 Strand, L., 648
 Stratton, Charles W., 334
 Streips, Uldis N., 83
 Studley, John G. N., 262
 Stull, Terrence L., 442
 Subramanian, R., 1031
 Sud, Inderjit, 470
 Sudan, Arthur W., 32
 Suffness, Matthew, 342
 Sugata, Toshiaki, 308
 Suhara, Yasuji, 611, 617
 Sundelof, Jon G., 62
 Sutherland, Robert, 369
 Suzuki, Yasuo, 250
 Swartz, Morton N., 662
 Sweet, Richard L., 711
 Swenson, Jana M., 186
 Sykes, Richard B., 414
 Sylvestre, M., 277
 Symchowicz, Samson, 1017
 Tachibana, A., 935
 Tai, M., 728
 Takahashi, Ikuko, 775
 Takahata, M., 728
 Tally, Francis P., 771
 Tanida, Seiichi, 735
 Taniyasu, Fumiko, 585
 Tardif, Ginette, 142
 Tarpay, Martha M., 145
 Tasker, D. Gordon, 170
 Taylor, Floyd B., 839
 Tee, Patricia E., 816
 Thadepalli, Haragopal, 350
 Thompson, Kenneth D., 426
 Thompson, Marietta I. B., 488
 Thompson, Sumner E., 409
 Thomson, Jennifer A., 689
 Thonus, Iwan P., 386
 Thornsberry, Clyde, 186, 859
 Tisone, JoAnn C., 903, 915, 920, 1082
 Tjandramaga, T. B., 237
 Tomasz, Alexander, 128
 Torney, Harry L., 635
 Tritton, Thomas R., 176, 284
 Troc, Kristine A., 426
 Ueda, Takao, 976
 Umeda, Isao, 611
 Umemura, Koshiro, 976
 Une, Tsutomu, 548
 Uwaydah, Marwan, 1087
 Väisänen, Vuokko, 120
 van den Berg, Joke C., 1042
 Van Den Broek, P. J., 593
 Van der Linden, M. P., 346
 Van Etta, Linda L., 844, 878
 Van Furth, R., 593
 Van Hecken, A., 237
 Van Landuyt, Herman W., 535
 Vaughn, James L., 527
 Vázquez, David, 255, 1070
 Verbesselt, R., 237
 Verbist, L., 237
 Verbist, Ludo, 157
 Verbrugh, Henri A., 781
 Verma, Mukesh, 541
 Veselenak, James M., 810
 Wade, James C., 193
 Wagner, Jutta, 1061
 Wall, Michael, 482
 Walton, Leslie, 882
 Wannemuehler, Yvonne M., 115
 Ward, Thomas T., 289
 Washington, J. A., II, 448
 Washington, John A., II, 461, 972
 Watanakunakorn, Chatrchai, 903, 915, 920, 1082
 Weaver, Susanne, 513
 Weber, A., 140
 Weiner, Ronald M., 527
 Welch, David F., 145, 493
 Wenk, Markus, 954
 Wennersten, Christine, 295
 Werkmeister, Ulrich, 302
 Westmacott, Donald, 571
 Weyant, Robbin S., 272
 Whelan, William L., 810
 White, James R., 961
 Wiernik, Peter H., 193
 Williams, Carol C., 499
 Wilson, Christopher B., 442
 Wilson, W. R., 448
 Wilson, Walter R., 972
 Winslow, Dean L., 51
 Winters, Maureen B., 662
 Wise, R., 969
 Witte, Joyce L., 906
 Wolfson, John S., 662
 Wolny, James D., 94
 Wood, Bruce A., 32
 Worley, Samuel E., 909
 Wright, A. J., 448
 Wright, Alan J., 972
 Wright, Donald N., 493
 Yamaguchi, Kazuo, 250
 Yano, K., 935
 Yano, Kuniichiro, 213
 Yasuda, T., 728
 Yasui, Victor K., 90
 Yee, Robert B., 839
 Yeowell, Heather N., 961
 Yokoshima, Tetsuyoshi, 976
 Yoneda, Masahiko, 735
 Yotsuji, A., 728
 Yourassowsky, E., 346
 Yu, Victor L., 839, 1076
 Zabransky, R. J., 628
 Zaphyr, M. K., 839
 Zaske, Darwin E., 391
 Zhang, Zhen-Xi, 421
 Zimmer, Barbara L., 148
 Zmerilli, S., 1084
 Zuravleff, Jeffrey J., 839

SUBJECT INDEX

VOLUME 22

- 1-Acetic acid-2-methyl-5-nitroimidazole
B. fragilis, 165
- 2-Acetylpyridine thiosemicarbazones
P. falciparum, 981
- Acinetobacter calcoaceticus*
 ceftriaxone, 1
 E-0702, 181
- Acinetobacter* sp.
 transposon-mediated multiple antibiotic resistance, 323
- Acriflavin
S. faecium, 295
- Acyclovir
 combined with vidarabine, 499
 herpes simplex virus, 71, 499
- Aeromonas hydrophila*
 β -lactams, 513
- 2-Alkynoic acids
 in vitro cell growth, 805
- Allopurinol
 4-aminopyrazolopyrimidine, 380
Leishmania spp., 380
T. cruzi, 657
- Amikacin
 combined with *N*-formimidoyl thienamycin, 1064
 comparative activity
 cefmenoxime, 316
 dosing methods
 granulocytopenic cancer patients, 193
 pharmacokinetic, 193
 standard, 193
Enterobacteriaceae, 985
 gram-negative bacilli, 1064
 inactivation by carbenicillin, 376
M. chelonae, 186
M. fortuitum, 186
 minimal antibiotic concentrations, 137
 renal failure, 376
S. aureus, 1064
 subbactericidal concentrations, 137
- Aminoglycoside-2'-*O*-adenylyltransferase
 7-hydroxytropolone, 824
- Aminoglycosides
 diffusion across *E. coli* outer membrane, 554
 minimal antibiotic concentrations, 137
M. melanosporea, 231
M. morgani, 218
M. purpurea, 231
P. alcalifaciens, 218
P. mirabilis, 218
P. rettgeri, 218
P. stuartii, 218
P. vulgaris, 218
 resistance during moxalactam therapy, 1037
 subbactericidal concentrations, 137
 synergism with cephalosporins, 743
- Aminomethylphosphonic acid
 phosphonopeptides, 571
- 4-Aminopyrazolopyrimidine
 allopurinol, 380
 2'-deoxyriboside derivative, 380
Leishmania spp., 380
- para-Aminosalicylic acid
M. chelonae, 186
M. fortuitum, 186
- Amoebicides
Brucea antidiysenterica, 342
 bruceantin, 342
- Amoscanate
 conversion to mutagenic metabolite
S. equinus in mice, 707
- Amoxicillin
 combined with clavulanic acid, 346, 353, 672
 distribution in animals, 369
 efficacy, 369
 gonococcal opacity variants, 515
 otitis media, 145
 pharmacokinetics, 353
S. pneumoniae, 145
 urinary tract infection, 346, 672
- Amphotericin B
 interactions with 5-fluorocytosine and ketoconazole
 pathogenic fungi, 763
- Ampicillin
B. asaccharolyticus, 698
B. melaninogenicus, 698
 combined with erythromycin
L. monocytogenes, 289
 combined with sulbactam
 colorectal surgery patients, 208
 comparative activity
 cefodizime, 715
 cefoperazone, 652
 ceftriaxone, 312
 moxalactam, 312
E. coli, 386
 effect on rifampin, 522
 gonococcal opacity variants, 515
 group B streptococci, 522
H. ducreyi, 686, 689
M. chelonae, 186
 meningitis, 652
M. fortuitum, 186
N. gonorrhoeae, 598
 otitis media, 145
S. faecium, 295
S. pneumoniae, 145
S. saprophyticus, 395
S. typhimurium, 312
 synergy
 fosmidomycin, 560
 urethral staphylococci, 395
 urinary tract infection, 1084
- Ampicillin-resistant bacteria
 cefoperazone, 15

- Anaerobic bacteria**
 cefoperazone, 338
 cefotaxime, 338
 ceftriaxone, 338
 metronidazole, 332, 426
 moxalactam, 338
 niridazole, 332
Anaerobic infections
 cancer patients
 moxalactam, 604
Anion-exchange extraction
 ceftizoxime, 336
 high-pressure liquid chromatography, 336
Antihypertensive compounds
 synergism
 BIOLF-62, 1026
 phosphonoformate, 1026
Apalcillin
 high-pressure liquid chromatography, 949
Aridone
 animals, 475
 intravaginal administration to mice, 475
 poliovirus in mice, 1022
 topical administration to mice, 475
Augmentin
 high-pressure liquid chromatography, 753
Azlocillin
 combined with cefotaxime
 blood isolates, 167
 compared with azlocillin-tobramycin, 167
 multidrug-resistant isolates, 167
 combined with clavulanic acid
 P. aeruginosa, 266
 combined with *N*-formimidoyl-thienamycin
 P. aeruginosa, 266
 combined with sulbactam
 P. aeruginosa, 266
 combined with tobramycin
 blood isolates, 167
 compared with azlocillin-ceftazoxime, 167
 multidrug-resistant isolates, 167
 compared with mezlocillin, 909
 disk diffusion susceptibility test
 interpretive criteria, 28
 quality control, 28
 meningitis, 909
 streptococci, 930
Azthreonam
 activity in vitro, 832
 gram-negative bacteria, 414
 hydrolysis
 renal dipeptidase, 693
 interaction with β -lactamase, 414
 pharmacokinetics, 969
 tissue penetration, 969

Bacillus subtilis
 extracellular protease, 83
 nafcillin, 83
Bacitracin
 S. faecium, 295
Bacterial infections
 ceftriaxone, 103
Bacteroides asaccharolyticus
 ampicillin, 698
 cephalixin, 698
 chloramphenicol, 698
 clindamycin, 698
 erythromycin, 698
 penicillin G, 698
 tetracycline, 698
Bacteroides fragilis
 clindamycin, 771
 metronidazole
 oxidative metabolites, 165
 penicillinase, 579
***Bacteroides fragilis* group**
 β -lactams
 indole production, 628
 pirlimycin, 893
Bacteroides melaninogenicus
 ampicillin, 698
 cephalixin, 698
 chloramphenicol, 698
 clindamycin, 698
 erythromycin, 698
 penicillin G, 698
 tetracycline, 698
***Bacteroides* spp.**
 cefoperazone, 398
 clavulanic acid, 398
 β -lactamase production, 398
 sulbactam, 398
 susceptibility to heavy metals, 889
Bacteroides thetaiotaomicron
 resistance transfer
 cefoxitin, 701
 clindamycin, 701
 erythromycin, 701
 lincomycin, 701
 tetracycline, 701
Benzylpenicillin
 N. gonorrhoeae, 598
 S. saprophyticus, 395
 urethral staphylococci, 395
Biliary tract surgery patients
 piperacillin, 488
BIOLF-62
 synergism
 antihypertensive compounds, 1026
 phosphonoformate, 1026
Black-pigmented *Bacteroides* spp.
 antibiotic susceptibility, 698
Bone cement diffusion
 guinea pigs
 cefamandole, 704
 penicillin, 704
 tobramycin, 704
BRL 17421
 in vitro activity, 157, 535
(E)-5-(2-Bromovinyl)-2'-deoxyuridine
 herpes simplex virus encephalitis in mice, 421
Bruceantoin
 Entamoeba histolytica, 342

Cancer patients
 anaerobic infections
 moxalactam, 604
Candida albicans
 5-fluorocytosine, 482, 810

- interaction
 - phagocytic cells, 593
 - povidone-iodine compounds, 593
 - serotype distribution, 482
- Candida* spp.
 - ketoconazole, 917
- Capreomycin
 - M. chelonae*, 186
 - M. fortuitum*, 186
- Carbenicillin
 - amikacin inactivation, 376
 - B. fragilis* group
 - indole production, 628
 - gentamicin inactivation, 376
 - P. aeruginosa*, 255
 - P. aeruginosa* resistance
 - azlocillin, 266
 - clavulanic acid, 266
 - N*-formimidoyl thienamycin, 266
 - sulbactam, 266
 - renal failure, 376
 - synergy
 - fosmidomycin, 560
- Carpetimycins
 - hydrolysis
 - renal dipeptidase, 693
- Cathra replicator
 - S. aureus*, 901
- Cefaclor
 - H. influenzae* type b susceptibility
 - inoculum size, 923
 - otitis media, 145
 - pharmacokinetics, 1061
 - S. faecium*, 295
 - S. pneumoniae*, 145
- Cefadroxil
 - pharmacokinetics, 1061
- Cefamandole
 - B. fragilis* group
 - indole production, 628
 - biliary excretion in rats, 170
 - comparative activity
 - cefmenoxime, 316
 - diffusion from bone cement
 - immunological responsiveness of guinea pigs, 704
 - excretion in pancreatic dogs, 262
 - gonococcal opacity variants, 515
 - hepatobiliary disease, 1087
 - M. chelonae*, 186
 - M. fortuitum*, 186
- Cefazedone
 - comparative activity
 - N*-formimidoyl thienamycin, 302
- Cefazolin
 - B. fragilis* group
 - indole production, 628
 - biliary excretion in rats, 170
 - comparative activity
 - SM-1652, 721
 - temocillin, 330
 - compared with cefazolin, 32
 - intramuscular administration, 201
 - intravenous administration, 201
 - K. pneumoniae*, 330, 1042
 - penetration into atrial appendage, 201
 - penetration into cortical bone in dogs, 461
- synergy
 - fosmidomycin, 560
- urinary tract infection, 32
- Cefmenoxime, 930
 - comparative activity
 - amikacin, 316
 - cefamandole, 316
 - cefoperazone, 316
 - cefotaxime, 316
 - cefoxitin, 316
 - ceftazidime, 316
 - ceftizoxime, 316
 - moxalactam, 316
 - piperacillin, 316
 - SM-1652, 721
 - tobramycin, 316
 - in vitro activity, 316
 - β -lactamase stability, 316
 - Y. enterocolitica*, 140
- Cefmetazole
 - comparative activity
 - SM-1652, 721
 - M. fortuitum*, 1079
- Cefodizime
 - comparative activity
 - ampicillin, 715
 - cefoperazone, 715
 - cefotaxime, 715
 - cephalothin, 715
 - gentamicin, 715
 - moxalactam, 715
 - oxacillin, 715
- Cefoperazone
 - aerobic bacteria, 226
 - aminoglycoside-resistant gram-negative bacilli, 154
 - ampicillin-resistant bacteria, 15
 - anaerobic bacteria, 226, 711
 - Bacteroides* spp., 398
 - B. fragilis* group
 - indole production, 628
 - combined with clavulanic acid
 - Bacteroides* spp., 398
 - β -lactamase production, 398
 - combined with sulbactam
 - Bacteroides* spp., 398
 - β -lactamase production, 398
 - comparative activity
 - ampicillin, 652
 - cefmenoxime, 316
 - cefodizime, 715
 - cefotaxime, 154
 - cefoxitin, 999
 - ceftriaxone, 338
 - chloramphenicol, 652
 - N*-formimidoyl thienamycin, 302
 - gentamicin, 652
 - moxalactam, 154
 - penicillin, 652
 - piperacillin, 154
 - SM-1652, 721
 - disk content, 493
 - disk susceptibility testing, 493
 - facultative bacteria, 226
 - fungi, 226
 - high-pressure liquid chromatography, 1076
 - β -lactamase production

- meningitis, 652
- pelvic infections in women, 711
- regression analysis, 493
- Ceforanide
 - dose regimens
 - vaginal hysterectomies, 643
- Cefotaxime, 930
 - aminoglycoside-resistant gram-negative bacilli, 154
 - anaerobic bacteria
 - pelvic infections in women, 711
 - B. fragilis* group
 - indole production, 628
 - combined with azlocillin
 - blood isolates, 167
 - compared with azlocillin-tobramycin, 167
 - multidrug-resistant isolates, 167
 - comparative activity
 - cefmenoxime, 316
 - cefodizime, 715
 - cefoperazone, 154
 - ceftriaxone, 338
 - moxalactam, 154
 - piperacillin, 154
 - SM-1652, 721
 - distribution
 - serum protein binding, 844
 - N*-formimidoyl thienamycin, 302
 - K. pneumoniae*, 1042
 - N. gonorrhoeae*, 598
 - Y. enterocolitica*, 140
- Cefotetan
 - comparative activity
 - cephems, 859
 - disk diffusion, 859
 - β -lactamase stability, 859
 - M. fortuitum*, 1079
 - pharmacokinetics in humans, 935
- Cefotiam
 - pharmacokinetics, 958
- Cefoxitin
 - anaerobic bacteria
 - pelvic infections in women, 711
 - B. fragilis* group
 - indole production, 628
 - biliary excretion in rats, 170
 - B. thetaiotaomicron*
 - resistance transfer, 701
 - comparative activity
 - cefmenoxime, 316
 - cefoperazone, 999
 - concentration in gallbladder bile
 - cholecystectomy patients, 709
 - gonococcal opacity variants, 515
 - H. ducreyi*, 686
 - M. chelonae*, 186
 - M. fortuitum*, 186, 1079
 - N. gonorrhoeae*, 598
 - pipecolic acid amide, 350
- Cefsulodin
 - comparative activity
 - SM-1652, 721
- Ceftazidime
 - comparative activity
 - cefmenoxime, 316
 - moxalactam, 237
 - K. pneumoniae*, 1042
 - N. gonorrhoeae*, 598
 - penetration into extravascular fluid, 995
 - pharmacokinetics, 237
 - Y. enterocolitica*, 140
- Ceftizoxime
 - anion-exchange extraction, 336
 - comparative activity
 - cefmenoxime, 316
 - distribution, 844, 878
 - elimination kinetics, 308
 - high-pressure liquid chromatography, 336
 - pharmacokinetics in humans, 878
 - protein binding, 844, 878
 - Y. enterocolitica*, 140
- Ceftriaxone
 - anaerobic bacteria, 338
 - bacterial infections, 103
 - bactericidal activity, 622
 - comparative activity
 - cefoperazone, 338
 - cefotaxime, 338
 - moxalactam, 338
 - comparative efficacy
 - ampicillin, 312
 - moxalactam, 312
 - Enterobacteriaceae*, 1
 - gram-negative bacilli, 1
 - N. gonorrhoeae*, 598
 - pharmacokinetics, 622, 816
 - serious infection, 36
 - S. typhimurium*, 312
 - Y. enterocolitica*, 140
- Cefuroxime
 - bacterial meningitis, 990
 - biliary excretion in rats, 170
 - comparative activity
 - N*-formimidoyl thienamycin, 302
 - penicillin, 409
 - gonorrhea, 409
 - M. chelonae*, 186
 - M. fortuitum*, 186
 - N. gonorrhoeae*, 598
 - pharmacokinetics, 990
- Cephalexin
 - B. asaccharolyticus*, 698
 - B. melaninogenicus*, 698
 - S. faecium*, 295
 - S. saprophyticus*, 395
 - synergy
 - fosmidomycin, 560
 - urethral staphylococci, 395
- Cephaloridine
 - biliary excretion in rats, 170
 - H. ducreyi*, 686
 - hydrolysis
 - renal dipeptidase, 693
- Cephalosporin derivatives
 - group B streptococci, 897
- Cephalosporins
 - biliary excretion in rats, 170
 - cefamandole
 - excretion in pancreatic dogs, 262
 - cefazolin
 - penetration into cortical bone in dogs, 461
 - cephalothin
 - excretion in pancreatic dogs, 262
 - E-0702, 181
 - M. morganii*, 218

- P. alcalifaciens*, 218
P. mirabilis, 218
P. rettgeri, 218
P. stuartii, 218
P. vulgaris, 218
 pyridinium-2-azo-*p*-dimethylaniline chromophore, 162
 SM-1652
 pharmacokinetics in animals, 213
 synergism with aminoglycosides, 743
 Cephalothin
 B. fragilis group
 indole production, 628
 comparative activity
 cefodizime, 715
 dose regimens
 vaginal hysterectomies, 643
 excretion in pancreatic dogs, 262
 L. micdadei, 272
 M. chelonae, 186
 M. fortuitum, 186
 S. aureus, 781
 S. faecium, 295
 streptococci, 930
 Cephadrine
 biliary excretion in rats, 170
Chlamydia trachomatis
 β -lactams, 520
 Chloramphenicol
 anaerobic bacteria
 pelvic infections in women, 711
 B. asaccharolyticus, 698
 B. melaninogenicus, 698
 comparative activity
 cefoperazone, 652
 M. chelonae, 186
 meningitis, 652
 M. fortuitum, 186
 N. gonorrhoeae, 598
 pipecolic acid amide, 350
 resistance determinants
 E. coli, 912
 S. faecium, 295
 S. pneumoniae, 222
 Chloroquine
 P. falciparum resistance, 981
 Cholecystectomy patients
 cefoxitin
 concentration in gallbladder bile, 709
Citrobacter freundii
 E-0702, 181
 Clavulanic acid
 combined with amoxicillin, 346, 353, 672
 combined with azlocillin
 P. aeruginosa, 266
 combined with cefoperazone
 Bacteroides spp., 398
 β -lactamase production, 398
 combined with mecillinam, 518
 distribution in animals, 369
 efficacy, 369
 pharmacokinetics, 353
 urinary tract infection, 346, 672
 Clindamycin
 anaerobic bacteria
 pelvic infections in women, 711
 B. asaccharolyticus, 698
 B. fragilis, 771
 B. melaninogenicus, 698
 B. thetaiotaomicron
 resistance transfer, 701
 comparative activity
 pirimycin, 334
 M. chelonae, 186
 M. fortuitum, 186
 pipecolic acid amide, 350
 S. aureus, 334, 781
 S. faecium, 295
 Clorobiocin
 analogs, 622
 E. coli, 662
 Cloxacillin
 S. aureus, 364
 S. faecium, 295
 Colorectal surgery patients
 ampicillin, 208
 sulbactam, 208
 Coumermycin
 analogs, 662
 E. coli, 662
 S. faecium, 295
 Cycloserine
 M. chelonae, 186
 M. fortuitum, 186
 S. faecium, 295
 3-Decynoyl-*N*-acetylcystamine
 in vitro cell growth, 805
 Deoxycytidine
 5-halogenated analog cytotoxicity, 431
 2-Deoxy-D-glucose
 herpes simplex virus replication, 284
 Vero cell growth, 284
 4'-Deoxy-6'-*N*-methylamikacin
 resistance
 E. coli mutant plasmid, 78
 9,3'-Diacetylmedecamycin
 metabolites, 976
 2-(3,4-Dichlorophenoxy)-5-nitrobenzonitrile
 antiviral activity, 635
 mechanism of action, 635
 picornaviruses, 639
 Didemnins
 antiviral activity
 Rift Valley fever virus, 696
 RNA virus inhibition, 696
 Disk susceptibility testing
 cefoperazone, 493
 DL-8280
 activity in vitro and in vivo, 548
 Dnacin B₁
 E. coli, 735
 mechanism of action, 735
 Dosing methods
 amikacin
 granulocytopenic cancer patients, 193
 pharmacokinetic, 193
 standard, 193
 Doxycycline
 H. ducreyi, 686
 M. chelonae, 186
 M. fortuitum, 186
 N. gonorrhoeae, 598

- E-0702
activity in vitro, 181
- Encephalitis
herpes simplex virus in mice
(E)-5-(2-bromovinyl)-2'-deoxyuridine, 421
- Endocarditis
gentamicin, 972
penicillin, 972
- Entamoeba histolytica*
Brucea antidiysenterica, 342
bruceantin, 342
- Enterobacter cloacae*
ceftriaxone, 1
E-0702, 181
 β -lactams
outer membrane permeation, 585
- Enterobacteria
 β -lactamase-stable penicillins, 198
temocillin, 198
- Enterobacteriaceae*
amikacin, 985
- Enterococci
N-formimidoyl thienamycin, 448, 1082
gentamicin, 1082
rifampin, 915
tobramycin, 1082
vancomycin, 915
- Enviroxime
rhinovirus infection, 1004
- Enzyme immunoassay
compared with radioimmunoassay
gentamicin pharmacokinetics, 648
netilmicin, 954
- Erythromycin
B. asaccharolyticus, 698
B. melaninogenicus, 698
B. thetaiotaomicron
resistance transfer, 701
combined with ampicillin
L. monocytogenes, 289
combined with gentamicin
L. monocytogenes, 289
combined with penicillin
L. monocytogenes, 289
gonococcal opacity variants, 515
H. ducreyi, 686
L. micdadei, 272
L. pneumophila, 90
M. chelonae, 186
M. fortuitum, 186
otitis media, 145
S. faecium, 295
S. pneumoniae, 145, 222
S. saprophyticus, 395
streptococci, 930
urethral staphylococci, 395
- Escherichia coli*
ampicillin, 386
4'-deoxy-6'-N-methylamikacin resistance, 78
dnacin B₁, 735
DNA gyrase
clorobiocin, 662
coumermycin A1, 662
novobiocin, 662
E-0702, 181
gentamicin, 358
- growth
clorobiocin, 662
coumermycin A1, 662
novobiocin, 662
- β -lactams
outer membrane permeation, 585
- meccillinam, 1070
minocycline, 791
nocardicin A, 1070
- outer membrane diffusion
fradiomycin, 554
gentamicin, 554
kanamycin, 554
lividomycin, 554
mannosylparomomycin, 554
streptomycin, 554
- plasmids
resistance conferring to analogs, 912
transfer, 142
- pyelonephritogenic strains
adhesion, 120
fimbriation, 120
hemagglutination, 120
ultrastructure, 120
sulfadiazine, 120
sulfamethoxazole, 120
sulfathiazole, 120
tetracycline, 791
transport, 791
trimethoprim, 120
- Ethambutol
in vitro synergy
M. avium-intracellulare complex, 148
M. chelonae, 186
M. fortuitum, 186
- Ethionamide
M. chelonae, 186
M. fortuitum, 186
- 5-Fluorocytosine
C. albicans, 482, 810
interactions with amphotericin B and ketoconazole
pathogenic fungi, 763
- N-Formimidoyl thienamycin
anaerobic bacteria
pelvic infections in women, 711
bactericidal activity, 448
combined with amikacin, 1064
combined with azlocillin
P. aeruginosa, 266
- comparative activity
cefazidone, 302
cefoperazone, 302
cefotaxime, 302
cefuroxime, 302
mezlocillin, 302
moxalactam, 302
ticarcillin, 406
tobramycin, 406
- derivatives, 62
enterococci, 448, 1082
gram-negative bacilli, 1064
hydrolysis
renal dipeptidase, 693
M. fortuitum, 1079
N. gonorrhoeae, 926

- N. meningitidis*, 926
P. aeruginosa pneumonia, 406
S. aureus, 906, 1064
S. faecium, 295
 synergism
 gentamicin, 1082
 tobramycin, 1082
 Fortimicin
 M. chelonae, 186
 M. fortuitum, 186
 Fosmidomycin
 synergy
 ampicillin, 560
 carbenicillin, 560
 cefazolin, 560
 cephalexin, 560
 gentamicin, 560
 ticarcillin, 560
 trimethoprim, 560
 Fradiomycin
 diffusion across *E. coli* outer membrane, 554
- G413
 structure-activity relationship, 1067
 Gentamicin
 combined with erythromycin
 L. monocytogenes, 289
 combined with penicillin
 endocarditis, 972
 comparative activity
 cefodizime, 715
 cefoperazone, 652
 tobramycin, 791
 diffusion across *E. coli* outer membrane, 554
 E. coli, 358
 enterococci, 1082
 humans, 791
 inactivation by carbenicillin, 376
 L. micdadei, 272
 M. chelonae, 186
 meningitis, 652
 M. fortuitum, 186
 minimal antibiotic concentrations, 137
 M. melanosporea, 231
 M. purpurea, 231
 nephrotoxicity in rats, 508
 P. aeruginosa, 358
 P. aeruginosa resistance gene, 525
 pharmacokinetics, 1017
 enzyme immunoassay, 648
 radioimmunoassay, 648
 renal failure, 376
 S. faecium, 295
 synergism
 N-Formimidoyl thienamycin, 1082
 fosmidomycin, 560
 vancomycin, 903
 subbactericidal concentrations, 137
 Gonococcal opacity variants
 amoxicillin, 515
 ampicillin, 515
 cefamandole, 515
 cefoxitin, 515
 erythromycin, 515
 moxalactam, 515
 penicillin, 515
 tobramycin, 515
 Gonorrhea
 cefuroxime, 409
 penicillin, 409
 Gramicidin S
 spore outgrowth, 785
 transcription, 785
 transport, 785
 Gram-negative bacilli
 amikacin, 1064
 aminoglycoside resistance
 cefoperazone, 154
 cefotaxime, 154
 moxalactam, 154
 piperacillin, 154
 N-formimidoyl thienamycin, 1064
 Gram-negative bacteria
 aminoglycosides, 23
 β -lactamase
 aztreonam, 414
 monobactams, 414
 β -lactams, 23
 norfloxacin, 23
 piperacillin, 10
 trimethoprim, 23
 Gram-positive bacteria
 aminoglycosides, 23
 β -lactams, 23
 norfloxacin, 23
 piperacillin, 10
 trimethoprim, 23
 Group A Baculoviridae
 rifampin, 527
 Group A streptococci
 penicillin-resistant mutants, 128
 penicillin-tolerant mutants, 128
 Group B streptococci
 ampicillin, 522
 cephalosporin derivatives, 897
 β -lactams, 897
 penicillin derivatives, 897
 rifampin, 522
- Haemophilus ducreyi*
 ampicillin resistance
 plasmid coding, 689
 β -lactamase production
 ampicillin, 686
 cefoxitin, 686
 cephaloridine, 686
 doxycycline, 686
 erythromycin, 686
 minocycline, 686
 penicillin G, 686
 rifampin, 686
 sulfamethoxazole, 686
 sulfisoxazole, 686
 tetracycline, 686
 trimethoprim, 686
Haemophilus influenzae
 cefactor susceptibility
 inoculum size, 923
 mutation frequency to rifampin resistance, 531
 Heavy metals
 Bacteroides spp. resistance, 889

- Hepatobility disease
 cefamandole, 1087
- Herpes simplex virus
 acyclovir, 71, 499
 encephalitis in mice
 (E)-5-(2-bromovinyl)-2'-deoxyuridine, 421
 9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine, 55
 replication
 2-deoxy-D-glucose, 284
 methyl daunosamine, 176
 tromantadine, 1031
 vidarabine, 499
- High-pressure liquid chromatography
 anion-exchange extraction, 336
 cefaclor, 949
 augmentin, 753
 cefoperazone, 1076
 ceftizoxime, 336
 Sch 29482, 848
- HR-221
 see cefodizime
- 1-(2-Hydroxyethyl)-2-hydroxymethyl-5-nitroimidazole
B. fragilis, 165
- 9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]methyl]guanine
 herpes simplex virus, 55
 in vitro activity, 55
- 4-Hydroxypyrazolo[3,4-d]pyrimidine
 biological activity, 657
 metabolism, 657
T. cruzi, 657
- 7-Hydroxytropolone
 aminoglycoside-2"-O-adenylyltransferase, 824
- Imidazoles
 ketoconazole, 470
 miconazole, 470
- Indole production
B. fragilis group
 β -lactams, 628
- Isoniazid
 in vitro synergy
M. avium-intracellulare complex, 148
M. chelonae, 186
M. fortuitum, 186
- Josamycin
M. chelonae, 186
M. fortuitum, 186
- Kanamycin
 diffusion across *E. coli* outer membrane, 554
 in vitro synergy
M. avium-intracellulare complex, 148
M. chelonae, 186
M. fortuitum, 186
- Ketoconazole
Candida spp., 917
 interactions with amphotericin B and 5-fluorocytosine
 pathogenic fungi, 763
P. falciparum, 917
 pharmacokinetics, 43
S. aureus, 470
- Klebsiella pneumoniae*
 cefazolin, 330, 1042
 cefotaxime, 1042
 ceftazidime, 1042
 E-0702, 181
 temocillin, 330
- β -Lactamase
 cephalosporin, 564
 gram-negative bacteria
 azthreonam, 414
 monobactams, 414
 penicillin, 564
- β -Lactamase production
Bacteroides spp.
 cefoperazone, 398
 clavulanic acid, 398
 sulbactam, 398
- inhibition
P. aeruginosa, 266
P. aeruginosa
 azlocillin, 266
 clavulanic acid, 266
N-formimidoyl thienamycin, 266
 sulbactam, 266
- β -Lactamase testing
 pyridinium-2-azo-*p*-dimethylaniline chromophore, 162
- β -Lactam derivatives
 comparative activities, 302
- β -Lactams
A. hydrophila, 513
 aminoglycoside-resistant gram-negative bacilli, 154
 anaerobic bacteria
 pelvic infections in women, 711
B. fragilis group
 indole production, 628
C. trachomatis, 520
 diffusion, 775
 group B streptococci, 897
 hydrolysis
 renal dipeptidase, 693
 outer membrane permeation
E. cloacae, 585
E. coli, 585
P. mirabilis, 585
P. aeruginosa
 resistance gene mapping, 242
 permeation, 942
 resistance
 during moxalactam therapy, 1037
S. aureus, 172
S. faecium resistance, 295
 temocillin, 453, 535
- Legionella micdadei*
 cephalothin, 272
 erythromycin, 272
 gentamicin, 272
 penicillin G, 272
 rifampin, 272
- Legionella pneumophila*
 erythromycin, 90
 mycinamycin, 90

- rosaramicin, 90
- tylosin, 90
- Leishmania* spp.
 - allopurinol, 380
 - 4-aminopyrazolopyrimidine, 380
- Lincomycin
 - B. thetaiotaomicron*
 - resistance transfer, 701
- Listeria monocytogenes*
 - ceftriaxone, 1
 - erythromycin combinations
 - ampicillin, 289
 - gentamicin, 289
 - penicillin, 289
 - sulfamethoxazole
 - alone and with trimethoprim, 51
 - tetracycline resistance
 - L-forms, 678
 - trimethoprim
 - alone and with sulfamethoxazole, 51
- Lividomycin
 - diffusion across *E. coli* outer membrane, 554
- M12325
 - antiviral activity, 250
- Mannosylparomomycin
 - diffusion across *E. coli* outer membrane, 554
- MDL-860
 - antiviral activity, 635
 - mechanism of action, 635
 - picornaviruses, 639
- Mecillinam
 - combinations
 - clavulanic acid, 518
 - sulbactam, 518
 - E. coli*, 1070
 - S. faecium*, 295
- Meningitis
 - azlocillin, 909
 - cefoperazone comparative activity
 - ampicillin, 652
 - chloramphenicol, 652
 - gentamicin, 652
 - penicillin, 652
 - ceftriaxone
 - bactericidal activity in cerebrospinal fluid, 622
 - pharmacokinetics, 622
 - mezlocillin, 909
- Mercury resistance
 - hospitals, 852
- Methicillin
 - Cathra replicator, 901
 - S. aureus*, 364
- Methyl daunosamine
 - herpes simplex virus replication, 176
- Metronidazole
 - anaerobic bacteria, 332, 426
 - comparative activity
 - niridazole, 332
 - microaerophilic bacteria, 332
 - M. chelonae*, 186
 - M. fortuitum*, 186
 - oxidation products, 426
 - oxidative metabolites
 - B. fragilis*, 165
 - pelvic infections in women, 711
- Mezlocillin
 - comparative activity
 - N*-formimidoyl thienamycin, 302
- Miconazole
 - S. aureus*, 470
- Microaerophilic bacteria
 - metronidazole, 332
 - niridazole, 332
- Microdilution techniques
 - Titertek Multiscan, 151
- Micromonospora melanosporea*
 - gentamicin, 231
- Micromonospora purpurea*
 - gentamicin, 231
- Minocycline
 - comparative activity
 - tetracycline, 791
 - E. coli* transport, 791
 - H. ducreyi*, 686
 - M. chelonae*, 186
 - M. fortuitum*, 186
 - N. gonorrhoeae*, 598
- MK0787
 - see *N*-formimidoyl thienamycin
- Monobactams
 - azthreonam, 832
 - gram-negative bacteria, 414
 - β -lactamase interaction, 414
- Morganella morganii*
 - aminoglycosides, 218
 - cephalosporins, 218
- Moxalactam
 - aminoglycoside-resistant gram-negative bacilli, 154
 - anaerobic bacteria
 - pelvic infections in women, 711
 - anaerobic infections in cancer patients, 604
 - B. fragilis* group
 - indole production, 628
 - comparative activity
 - cefazolin, 32
 - cefmenoxime, 316
 - cefodizime, 715
 - cefoperazone, 154
 - cefotaxime, 154
 - ceftriaxone, 338
 - N*-formimidoyl thienamycin, 302
 - piperacillin, 154
 - SM-1652, 721
 - comparative efficacy
 - ampicillin, 312
 - ceftriaxone, 312
 - gonococcal opacity variants, 515
 - intramuscular administration, 201
 - intravenous administration, 201
 - M. fortuitum*, 1079
 - P. aeruginosa*, 1037
 - penetration into atrial appendage, 201
 - pharmacokinetics, 47, 94
 - compared with ceftazidime, 237
 - streptococci, 930
 - S. typhimurium*, 312
 - urinary tract infection, 32
 - Y. enterocolitica*, 140
- Mycinamycin
 - L. pneumophila*, 90
- Mycobacterium avium-intracellulare* complex
 - ethambutol, 148

- isoniazid, 148
- kanamycin, 148
- rifampin, 148
- streptomycin, 148
- Mycobacterium chelonae*
 - susceptibility
 - agar dilution, 186
 - broth microdilution, 186
- Mycobacterium fortuitum*
 - ceftazidime, 1079
 - cefotetan, 1079
 - cefoxitin, 1079
 - N-formimidoyl thienamycin, 1079
 - moxalactam, 1079
 - susceptibility
 - agar dilution, 186
 - broth microdilution, 186
- Nafcillin
 - antagonism with rifampin
 - S. aureus*, 920
 - B. subtilis* tolerance, 83
- Nalidixic acid
 - P. aeruginosa*
 - resistance gene mapping, 242
 - S. saprophyticus*, 395
 - urethral staphylococci, 395
- Neisseria gonorrhoeae*
 - cross-resistance, 598
 - E-0702, 181
 - N-formimidoyl thienamycin, 926
 - susceptibility in vitro, 598
- Neisseria meningitidis*
 - N-formimidoyl thienamycin, 926
- Netilmicin
 - enzyme immunoassay, 954
 - M. chelonae*, 186
 - M. fortuitum*, 186
 - minimal antibiotic concentrations, 137
 - pharmacokinetics, 1017
 - serum assay, 1058
 - subbactericidal concentrations, 137
- Nitridazole
 - anaerobic bacteria, 332
 - comparative activity
 - metronidazole, 332
 - microaerophilic bacteria, 332
- Nitrofurantoin
 - S. faecium*, 295
 - S. saprophyticus*, 395
 - urethral staphylococci, 395
- 4-Nitro-4'-isothiocyano-diphenylamine
 - conversion to mutagenic metabolite
 - S. equinus* in mice, 707
- Nocardicin A
 - E. coli*, 1070
- Norfloxacin
 - comparative activity
 - aminoglycosides, 23
 - β -lactams, 23
 - trimethoprim, 23
 - gram-negative bacteria, 23
 - gram-positive bacteria, 23
- Novobiocin
 - analogs, 662
 - E. coli*, 662
- S. faecium*, 295
- S. saprophyticus*, 395
- urethral staphylococci, 395
- Nuclear polyhedrosis virus
 - rifampin, 527
- Otitis media
 - S. pneumoniae*
 - amoxicillin, 145
 - ampicillin, 145
 - cefaclor, 145
 - erythromycin, 145
 - penicillin G, 145
 - sulfamethoxazole, 145
 - sulfisoxazole, 145
 - trimethoprim, 145
- Oxacillin
 - antagonism with rifampin
 - S. aureus*, 920
 - comparative activity
 - cefodizime, 715
- Oxazine derivatives
 - DL-8280, 548
- Oxolinic acid
 - S. faecium*, 295
- P. aeruginosa*
 - moxalactam, 1037
- Pancreatitis
 - cefamandole
 - excretion in dogs, 262
 - cephalothin
 - excretion in dogs, 262
- Penicillin
 - combined with erythromycin
 - L. monocytogenes*, 289
 - combined with gentamicin
 - endocarditis, 972
 - comparative activity
 - cefoperazone, 652
 - cefuroxime, 409
 - gonococcal opacity variants, 515
 - gonorrhea, 409
 - β -lactamase stable
 - temocillin, 157
 - meningitis, 652
 - resistance
 - group A streptococci, 128
 - S. aureus*, 781
 - S. pneumoniae*, 222
 - streptococci tolerance, 128, 1073
- Penicillinase
 - B. fragilis*, 579
- Penicillin-binding proteins
 - S. aureus*, 172
- Penicillin derivatives
 - group B streptococci, 897
- Penicillin G
 - anaerobic bacteria
 - pelvic infections in women, 711
 - B. asaccharolyticus*, 698
 - B. melaninogenicus*, 698
 - diffusion from bone cement
 - immunological responsiveness of guinea pigs, 704
 - H. ducreyi*, 686

- hydrolysis
 - renal dipeptidase, 693
- L. micdadei*, 272
- M. chelonae*, 186
- M. fortuitum*, 186
- otitis media, 145
- S. faecium*, 295
- S. pneumoniae*, 145
- streptococci, 930
- Penicillins
 - enterobacteria, 198
 - β -lactamase stability, 198
 - P. aeruginosa*, 198
 - temocillin, 198
- Phagocytic cells
 - interaction
 - C. albicans*, 593
 - povidone-iodine compounds, 593
- Pharmacokinetics
 - amoxicillin, 353
 - aztreonam, 969
 - cefaclor, 1061
 - cefadroxil, 1061
 - cefotetan, 935
 - cefotiam, 958
 - ceftazidime, 237
 - ceftizoxime, 878
 - ceftriaxone, 816
 - cefuroxime, 990
 - clavulanic acid, 353
 - enzyme immunoassay, 648
 - gentamicin, 648, 1017
 - ketoconazole, 43
 - moxalactam, 47, 94, 237
 - netilmicin, 1017
 - piperacillin in children, 442
 - radioimmunoassay, 648
 - SM-1652
 - animals, 213
 - tobramycin, 1017
 - vancomycin, 391
- Phosphonoformate
 - synergism
 - antihypertensive compounds, 1026
 - BIOLF-62, 1026
- Phosphonopeptides
 - aminomethylphosphonic acid-based, 571
- Picornaviruses
 - 2-(3,4-dichlorophenoxy)-5-nitrobenzonitrile, 639
 - MDL-860, 639
 - Ro 09-0179, 611
- Piperacillin, 930
 - aminoglycoside-resistant gram-negative bacilli, 154
 - anaerobic bacteria
 - pelvic infections in women, 711
 - biliary tract surgery patients, 488
 - comparative activity
 - cefmenoxime, 316
 - cefoperazone, 154
 - cefotaxime, 154
 - moxalactam, 154
 - gram-negative bacteria, 10
 - gram-positive bacteria, 10
 - pharmacokinetics in children, 442
 - therapeutic efficacy, 10
 - tolerability, 10
- Pirlimycin
 - B. fragilis* group, 893
 - comparative activity
 - clindamycin, 334
 - S. aureus*, 334
- Plasmodium falciparum*
 - 2-acetylpyridine thiosemicarbazones, 981
 - ketoconazole, 917
- Pneumonia
 - N*-formimidoyl thienamycin, 406
 - P. aeruginosa*, 406
 - ticarcillin, 406
 - tobramycin, 406
- Poliovirus
 - arildone in mice, 1022
- Polymyxin
 - P. aeruginosa*, 1012
- Porin proteins
 - role in β -lactam permeation, 942
- Povidone-iodine compounds
 - interaction
 - C. albicans*, 593
 - phagocytic cells, 593
- Proteus inconstans*
 - E-0702, 181
- Proteus mirabilis*
 - aminoglycosides, 218
 - cephalosporins, 218
 - E-0702, 181
 - β -lactams
 - outer membrane permeation, 585
- Proteus morganii*
 - E-0702, 181
- Proteus rettgeri*
 - E-0702, 181
- Proteus vulgaris*
 - aminoglycosides, 218
 - cephalosporins, 218
 - E-0702, 181
- Providencia alcalifaciens*
 - aminoglycosides, 218
 - cephalosporins, 218
- Providencia rettgeri*
 - aminoglycosides, 218
 - cephalosporins, 218
- Providencia stuartii*
 - aminoglycosides, 218
 - cephalosporins, 218
- Pseudomonas aeruginosa*
 - aminoglycoside detection, 525
 - carbenicillin, 255
 - carbenicillin resistance
 - azlocillin, 266
 - clavulanic acid, 266
 - N*-formimidoyl thienamycin, 266
 - sulbactam, 266
 - ceftriaxone, 1
 - E-0702, 181
 - production of β -lactamase
 - azlocillin, 266
 - clavulanic acid, 266
 - N*-formimidoyl thienamycin, 266
 - sulbactam, 266
 - β -lactamase-stable penicillins, 198
 - β -lactams, 242

- nalidixic acid, 242
 plasmids
 E. coli, 358
 gentamicin, 358
 transfer, 142
 polymyxin, 1012
 resistance gene
 cloning, 525
 mapping, 242
 temocillin, 198
 ticarcillin, 839
 tobramycin, 839
Pseudomonas aeruginosa pneumonia
 N-formimidoyl thienamycin, 406
 ticarcillin, 406
 tobramycin, 406
Pseudomonas cepacia
 E-0702, 181
Pseudomonas fluorescens
 T. cruzi, 1051
Pseudomonas maltophilia
 E-0702, 181
 β -lactamase
 cephalosporin, 564
 penicillin, 564
 Pyridinium-2-azo-*p*-dimethylaniline chromophore
 β -lactamase testing, 162
- Radiomunoassay
 compared with enzyme immunoassay
 gentamicin pharmacokinetics, 648
 Renal dipeptidase
 hydrolysis
 aztreonam, 693
 carpetimycins A and B, 693
 cephaloridine, 693
 N-formimidoyl thienamycin, 693
 penicillin G, 693
 Sch 29482, 693
 Renal dysfunction
 ceftizoxime, 308
 Resistance gene mapping
 β -lactams, 242
 nalidixic acid, 242
 P. aeruginosa, 242
 Resistance patterns
 S. pneumoniae, 222
 Rhinoviruses
 enviroxime, 1004
 inactivation by Ro 09-0410, 617
 Ribavirin
 lymphocyte inhibition, 108
 Ribosomal resistance
 aminoglycosides, 231
 gentamicin, 231
 M. melanosporea, 231
 M. purpurea, 231
 Rifampin
 ampicillin, effect on, 522
 antagonism
 nafcillin, 920
 oxacillin, 920
 combined with vancomycin
 enterococci, 915
 group A Baculoviridae, 527
 group B streptococci, 522
- H. ducreyi*, 686
H. influenzae mutation frequency, 531
 in vitro synergy
 M. avium-intracellulare complex, 148
L. micdadei, 272
M. chelonae, 186
M. fortuitum, 186
 Rift Valley fever virus
 didemnins, 696
 RNA viruses
 didemnins, 696
 Ro 09-0179
 antiviral activity, 611
 Ro 09-0410
 rhinovirus inactivation, 617
 Ro 13-9904
 serious infection, 36
 Rosaramicin
 L. pneumophila, 90
 M. chelonae, 186
 M. fortuitum, 186
 N. gonorrhoeae, 598
 Rosoxacin
 N. gonorrhoeae, 598
 R-plasmids
 transfer from *S. faecalis* to *S. aureus*, 204
- Salmonella* spp.
 E-0702, 181
Salmonella typhimurium
 ampicillin, 312
 ceftriaxone, 312
 moxalactam, 312
 thiolitin resistance, 541
 Sch 29482
 high-pressure liquid chromatography, 848
 hydrolysis
 renal dipeptidase, 693
Serratia marcescens
 E-0702, 181
 Serum protein binding
 antibiotic distribution, 844
 ceftizoxime, 878
 Sisomicin
 M. chelonae, 186
 M. fortuitum, 186
 SM-1652
 comparative activity
 cefazolin, 721
 cefmenoxime, 721
 cefmetazole, 721
 cefoperazone, 721
 cefotaxime, 721
 cefsulodin, 721
 moxalactam, 721
 pharmacokinetics in animals, 213
 Sodium 5-aminosulfonyl-2,4-dichlorobenzoate
 antiviral activity, 250
 Spectinomycin
 N. gonorrhoeae, 598
 SQ 26,776
 Y. enterocolitica, 140
 Staphylococci
 antagonococcal activity
 characterization, 277

- production, 277
- purification, 277
- Staphylococcus aureus*
 - amikacin, 1064
 - Cathra replicator, 901
 - ceftriaxone, 1
 - cephalothin, 781
 - clindamycin, 334, 781
 - cloxacillin, 364
 - E-0702, 181
 - N-formimidoyl thienamycin, 906, 1064
 - ketoconazole, 470
 - β -lactam-resistance
 - penicillin-binding proteins, 172
 - methicillin, 364
 - miconazole, 470
 - nafticin, 920
 - oxacillin, 920
 - penicillin, 781
 - pirlimycin, 334
 - rifampin, 920
 - R-plasmid transfer from *S. faecalis*, 204
 - vancomycin synergism
 - gentamicin, 903
 - tobramycin, 903
- Staphylococcus epidermidis*
 - E-0702, 181
- Staphylococcus saprophyticus*
 - ampicillin, 395
 - benzylpenicillin G, 395
 - cephalexin, 395
 - erythromycin, 395
 - nalidixic acid, 395
 - nitrofurantoin, 395
 - novobiocin, 395
 - sulfamethoxazole, 395
 - trimethoprim, 395
- Streptococci*
 - azlocillin, 930
 - cefmenoxime, 930
 - cefotaxime, 930
 - cephalothin, 930
 - erythromycin, 930
 - moxalactam, 930
 - penicillin G, 930
 - penicillin tolerance, 1073
 - piperacillin, 930
 - vancomycin, 930
- Streptococcus equinus*
 - amoscanate conversion to mutagenic metabolite mice, 707
- Streptococcus faecalis*
 - R-plasmid transfer to *S. aureus*, 204
- Streptococcus faecium*
 - β -lactams, 295
- Streptococcus mutans*
 - iodine, 115
 - pH values, 115
 - sodium fluoride, 115
- Streptococcus pneumoniae*
 - chloramphenicol, 222
 - erythromycin, 222
 - otitis media
 - amoxicillin, 145
 - ampicillin, 145
 - cefaclor, 145
 - erythromycin, 145
 - penicillin G, 145
 - sulfamethoxazole, 145
 - sulfisoxazole, 145
 - trimethoprim, 145
- penicillin, 222
- resistance patterns, 222
- serotype distribution, 222
- tetracycline, 222
- Streptomycin
 - diffusion across *E. coli* outer membrane, 554
 - in vitro synergy
 - M. avium-intracellulare* complex, 148
- Streptonigrin
 - bacterial mechanism, 961
- Sulbactam
 - combined with ampicillin
 - colorectal surgery patients, 208
 - combined with azlocillin
 - P. aeruginosa*, 266
 - combined with cefoperazone
 - Bacteroides* spp., 398
 - β -lactamase production, 398
 - combined with mecillinam, 518
- Sulfadiazine
 - E. coli*
 - adhesion, 120
 - fimbriation, 120
 - hemagglutination, 120
 - ultrastructure, 120
- Sulfadiazole
 - E. coli*
 - adhesion, 120
 - fimbriation, 120
 - hemagglutination, 120
 - ultrastructure, 120
- Sulfamethoxazole
 - combined with trimethoprim, 51, 186, 395, 686
 - E. coli*
 - adhesion, 120
 - fimbriation, 120
 - hemagglutination, 120
 - ultrastructure, 120
 - H. ducreyi*, 686
 - in vitro activity, 51
 - L. monocytogenes*, 51
 - M. chelonae*, 186
 - M. fortuitum*, 186
 - otitis media, 145
 - S. pneumoniae*, 145
 - S. saprophyticus*, 395
 - urethral staphylococci, 395
- Sulfisoxazole
 - H. ducreyi*, 686
 - otitis media, 145
 - S. pneumoniae*, 145
- Susceptibility testing
 - azlocillin, 28
- Synergism
 - aminoglycosides and cephalosporins, 743
 - interaction index, 743
 - killing curve method, 743
- T-1982
 - comparative activity
 - cefazolin, 728
 - cefmetazole, 728

- cefoperazone, 728
 cefoxitin, 728
 gram-negative bacteria, 728
 gram-positive bacteria, 728
Temocillin
 antibacterial activity, 453
 comparative activity
 cefazolin, 330
 cefotaxime, 535
 ceftazidime, 535
 cephalothin, 535
 moxalactam, 535
 piperacillin, 535
 enterobacteria, 198
 in vitro activity, 157, 198, 535
 K. pneumoniae, 330
 β -lactamase stability, 453
 P. aeruginosa, 198
Tetracycline
 B. asaccharolyticus, 698
 B. melaninogenicus, 698
 B. thetaiotaomicron
 resistance transfer, 701
 comparative activity
 minocycline, 791
 E. coli transport, 791
 H. ducreyi, 686
 L. monocytogenes resistance
 L-forms, 678
 M. chelonae, 186
 M. fortuitum, 186
 N. gonorrhoeae, 598
 S. pneumoniae, 222
Thiamphenicol
 M. chelonae, 186
 M. fortuitum, 186
Thienamycin
 metabolism by dehydropeptidase-I, 62
Thiolutin
 S. typhimurium resistance, 541
Ticarcillin
 combined with tobramycin, 839
 comparative activity
 N-formimidoyl thienamycin, 406
 tobramycin, 406
 P. aeruginosa, 839
 P. aeruginosa pneumonia, 406
 synergy
 fosmidomycin, 560
Titertek Multiscan
 minimal inhibitory concentration endpoints, 151
Tobramycin
 combined with azlocillin
 blood isolates, 167
 comparison with azlocillin-cefotaxime, 167
 multidrug-resistant isolates, 167
 combined with ticarcillin, 839
 comparative activity
 cefmenoxime, 316
 N-formimidoyl thienamycin, 406
 gentamicin, 791
 ticarcillin, 406
 diffusion from bone cement
 immunological responsiveness of guinea pigs, 704
 enterococci, 1082
 gonococcal opacity variants, 515
 humans, 791
 M. chelonae, 186
 M. fortuitum, 186
 minimal antibiotic concentrations, 137
 P. aeruginosa, 839
 P. aeruginosa pneumonia, 406
 pharmacokinetics, 1017
 S. faecium, 295
 subbactericidal concentrations, 137
 synergism
 N-Formimidoyl thienamycin, 1082
 vancomycin, 903
Trimethoprim
 combined with sulfamethoxazole, 51, 186
 H. ducreyi, 686
 S. saprophyticus, 395
 urethral staphylococci, 395
E. coli
 adhesion, 120
 fimbriation, 120
 heparinagglutination, 120
 ultrastructure, 120
 H. ducreyi, 686
 in vitro activity, 51
 L. monocytogenes, 51
 M. chelonae, 186
 M. fortuitum, 186
 otitis media, 145
 resistance
 dihydrofolate reductase genes, 882
 S. pneumoniae, 145
 synergy
 fosmidomycin, 560
Tromantadine
 herpes simplex virus replication, 1031
Trypanosoma brucei
 tunicamycin, 1008
Trypanosoma cruzi
 bloodstream form
 allopurinol, 657
 intracellular form
 allopurinol, 657
 P. fluorescens, 1051
Tunicamycin
 T. brucei, 1008
Tylosin
 L. pneumophila, 90
Tyrocidines
 spore outgrowth, 785
 transcription, 785
 transport, 785

U-57930E
 see pirlimycin
Urethral staphylococci
 ampicillin, 395
 benzylpenicillin G, 395
 cephalexin, 395
 erythromycin, 395
 nalidixic acid, 395
 nitrofurantoin, 395
 novobiocin, 395
 sulfamethoxazole, 395
 trimethoprim, 395
Urinary tract infection
 amoxicillin, 346, 672
 clavulanic acid, 346, 672

Vaginal hysterectomies
 comparative dose regimens
 ceforanide, 643
 cephalothin, 643
 Vancomycin
 combined with rifampin
 enterococci, 915
 dosage recommendations, 391
 M. chelonae, 186
 M. fortuitum, 186
 pharmacokinetics, 391
 S. faecium, 295
 streptococci, 930
 synergism
 gentamicin, 903
 tobramycin, 903

Vidarabine
 combined with acyclovir, 499
 herpes simplex virus, 499

Yersinia enterocolitica
 cefmenoxime, 140
 cefotaxime, 140
 ceftazidime, 140
 ceftizoxime, 140
 ceftriaxone, 140
 moxalactam, 140
 SQ 26,776, 140
 YM09330
 see cefotetan